Business Context and Reporting Period
Company: NeoGenomics, Inc. (NEO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: NeoGenomics provides oncology diagnostic testing, consultative services, and pharmaceutical development support through a network of laboratories in the U.S. and U.K. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Revenue | $201,656 | $181,330 | $388,328 | $349,365 |
| Gross Profit | $91,878 | $77,258 | $172,742 | $150,504 |
| Gross Margin | 45.6% | 42.6% | 44.5% | 43.1% |
| Net Income (Loss) | $2,238 | $(45,092) | $(14,868) | $(71,015) |
| Adjusted EBITDA (Non-GAAP) | $14,467 | $10,675 | $23,471 | $17,745 |
| Cash and Equivalents (End of Period) | $145,539 | $154,723 | $145,539 | $154,723 |
| Working Capital | $275,595 | $292,433 | $275,595 | $292,433 |
| Total Debt (Convertible Notes, net) | $374,241 | $341,858 | $374,241 | $341,858 |
Note: Q2 2026 Net Income includes a one-time gain on debt extinguishment of $11.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11.2% year-over-year for both the quarter and six months ended June 30, 2026, driven by higher test volumes and strategic reimbursement initiatives, partially offset by lower non-clinical revenue due to macro trends in the pharmaceutical industry.
- Profitability Improvement: The company returned to profitability in Q2 2026 ($2.2M net income) compared to a significant loss in Q2 2025 ($45.1M). This improvement is largely attributable to the absence of $20.0M in impairment charges recorded in the prior year and a $11.2M gain on debt extinguishment.
- Expense Management: General and Administrative (G&A) expenses decreased 11.3% in Q2 2026, driven by lower legal fees and a $1.2M benefit from the reversal of a regulatory settlement accrual. Sales and Marketing expenses increased 13.3% due to sales force expansion.
- Debt Restructuring: In June 2026, the company issued $316.3M in 0.75% Convertible Senior Notes due 2032. Proceeds were used to repurchase $276.0M of its 2028 Convertible Notes, resulting in the aforementioned gain on extinguishment.
Guidance, Outlook, and Risks
- Capital Expenditures: Management forecasts full-year 2026 capital expenditures to be in the range of $30.0 million to $35.0 million.
- Liquidity: The company holds $145.5 million in unrestricted cash and cash equivalents, deemed sufficient to fund operations for at least the next 12 months.
- Strategic Focus: Key initiatives include driving adoption of therapy selection and Molecular Residual Disease (MRD) portfolios, expanding community oncology market presence, and optimizing operational efficiency through automation.
- Regulatory Risks: The company faces evolving regulatory scrutiny regarding Laboratory Developed Tests (LDTs). While a recent court decision vacated an FDA final rule, future legislative or administrative actions could increase compliance costs and burdens.
- Legal Contingencies: A $10.0 million settlement with the U.S. Department of Justice regarding a regulatory investigation was finalized in July 2026. A $1.2M benefit was recognized in Q2 2026 due to the settlement amount being lower than the previously reserved $11.2M.
Investor Verification Checklist
- Debt Maturity Profile: Verify the impact of the new 2032 Convertible Notes and the remaining 2028 Notes on future cash flow and potential dilution.
- Regulatory Settlement: Confirm the timing and impact of the $10.0 million DOJ settlement payment expected in Q3 2026.
- Revenue Quality: Assess the sustainability of the 11.2% revenue growth given the noted decline in pharmaceutical clinical trial volumes.
- Impairment History: Review the $20.0M impairment charges from 2025 to ensure no further asset write-downs are anticipated for legacy technologies.
- Stock Repurchases: Note the $25.0 million share repurchase executed in June 2026 and its impact on outstanding share count and EPS.